Report Detail
Cancer Diagnostics Global Market - Forecast to 2026
- RnM4214914 |
- 25 September, 2020 |
- Global |
- 405 Pages |
- IQ4I Research & Consultancy |
- Other
The understanding of the pathways of cancer development and their causes has led to the development of novel methodologies, and there is an emerging trend towards precision health in today’s world to enhance cancer diagnosis, treatment, prevention and monitoring by using innovative diagnostic technologies with broader range.
Over the past few years technical advancements has led to the progression in cancer screening and treatment. The rise in number of new cases necessitates for more improvised technologies in diagnosis and monitoring of cancer. Cancer diagnostics are the foundation for the successful cancer prevention, where it provides quantitative measurements, changes at the genetic level thereby finding the underlying mechanism of disease and enabling the oncologist to tailor care at individual level and facilitating the personalized medicine practice.
Due to the side effects of radiation and other image-based diagnosis of cancer, there is a huge opportunity for non-image based techniques such as in-vitro diagnostics comprising tests based on molecular biology and immunology. These tests provide rapid and precise information about cancer and have revolutionized cancer management around the world. Some of the advantages of non-image based diagnostics are, up to 70% of the healthcare decisions are influenced by molecular and immune-based tests further improving the quality of personalized care of the patient, potential improvement in the patient outcome and facilitate early detection of cancer with sensitive assays thereby reducing the cost of healthcare of an individual.
According to IQ4I analysis, the cancer diagnostics global market is expected to reach $10,627.4 million by 2026 growing at a high single digit CAGR from 2019 to 2026. The growth of cancer diagnostic market is driven by the increasing number of cancer associated with the lifestyle, dramatic changes in the demography, advances in the disease genomics, also adoption of nationwide cancer screening programs as a part of national cancer control plans by individual countries (almost 120 countries have included national plans for cervical and breast cancer screening programs respectively) and discovery of new drugs. Cancer diagnostic tests have provided a greater value and are likely to play an escalating role in the future market.
The commercialization of cancer diagnostics techniques depends on economical, clinical and logistic challenges. One among them is the reimbursement system with suitable coding, positive coverage, and assessment of the price of novel diagnostics. With the reimbursement policies, all patients can access all new diagnostic tests on sustained bases thereby reducing the financial pressure. Also, high investment by major players for the production and release of new diagnostics techniques to the market will have a major role in driving the cancer diagnostics market. The restraints of the cancer diagnostics will include lack of skilled professionals, high cost of advanced techniques, product recall due to manufacturing defects and quality issues, stringent and time consumption for getting approvals from the regulatory bodies, lack of reimbursement will also hamper the growth of cancer diagnostic market.
The cancer diagnostics global market is segmented based on technology, sample source, application and end-users. The technology market is further categorized into immunoassays, molecular-based assays and others. The immunoassays global market is further sub-segmented into Immunohistochemistry (IHC), Enzyme Linked Immunosorbent Assay (ELISA) and others comprising of RIA (Radioimmunoassay), CLIA (Chemiluminescence), and FIA (Fluorescence immunoassays), among which, ELISA commanded the largest revenue in 2019, and IHC is expected to grow at a strong double digit CAGR from 2019 to 2026. The molecular-based global market is further sub-segmented into in-situ hybridization, PCR, microarray and sequencing, among which PCR commanded the largest revenue in 2019, the sequencing segment is expected to grow at a strong double digit CAGR from 2019 to 2026. The other technology segment is expected to grow at a mid single digit CAGR from 2019 to 2026.
Based on the source of the sample taken for performing the diagnostic test, the market is segmented into three categories, viz., blood, tissue and others. Among these segment, blood accounted for the largest revenue generation in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The blood-based tests provide accurate results when compare to tissue and other source and its less painful for collection from the individual compare to tissue and other source such as cerebrospinal fluid, bone marrow aspirate sample. Also, blood as a sample source can be used for early diagnosis before the occurrence of symptoms.
The cancer diagnostics by the application are classified into cancer type and cancer care segment. The market based on cancer type is further segmented into lung, breast, colorectal, prostate, ovarian, liver and other cancers. The largest revenue was generated by colorectal cancer in 2019 and is expected to grow at a strong double digit CAGR from 2019 to 2026. The cancer care segment is further classified into diagnosis, early screening, companion diagnostics, prognosis and monitoring. Among which, diagnosis accounted for the largest revenue in 2019 whereas, companion diagnostics segment is expected to grow at a strong double digit CAGR from 2019 to 2026.
The cancer diagnostics end-user market is segmented into hospitals, clinical/centralized laboratories, and other end-users such as biopharma, academics and research. Clinical/centralized laboratories segment accounted for the largest revenue in 2019 owing to the access of advanced and novel technologies for the diagnosis and also the availability of skilled professionals with more capital investments as compared with hospitals. Hospitals segment is expected to grow at a high single digit CAGR from 2019 to 2026.
Geographical wise, North America region commanded the largest revenue in 2019, owing to the high demand for early detection, treatment and prevention of cancer with advanced technology due to larger outbreaks of cancer associated with the lifestyle. However, the Asia-Pacific region is expected to grow at a strong double digit CAGR from 2019 to 2026 owing to higher incidence of cancer cases compare to other regions and also increasing awareness programmes on the need for screening and prevention of cancer at early stages.
The cancer diagnostics global market is a competitive market and all the existing players in this market are involved in developing new and advanced techniques for diagnosis to maintain their market shares and also acquiring companies for product expansion and technological innovations.
Some of the key players in cancer diagnostics global market are Abbott Laboratories (U.S.), F.Hoffmann-LA Roche AG (Switzerland), Qiagen (Netherlands), Exact Sciences Corporation (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), Hologic, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Siemens Healthineers (Germany), and Guardant Health (U.S.).
1 EXECUTIVE SUMMARY 22
2 INTRODUCTION 28
- 2.1 KEY TAKEAWAYS 28
- 2.2 SCOPE OF THE REPORT 28
- 2.3 REPORT DESCRIPTION 29
- 2.4 MARKETS COVERED 32
- 2.5 STAKEHOLDERS 33
- 2.6 RESEARCH METHODOLOGY 34
- 2.6.1 MARKET SIZE ESTIMATION 35
- 2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION 38
- 2.6.3 SECONDARY SOURCES 39
- 2.6.4 PRIMARY SOURCES 40
- 2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 40
- 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 41
- 2.6.7 ASSUMPTIONS 41
3 MARKET ANALYSIS 44
- 3.1 INTRODUCTION 44
- 3.2 MARKET SEGMENTATION 45
- 3.3 FACTORS INFLUENCING MARKET 47
- 3.3.1 DRIVERS AND OPPORTUNITY 47
- 3.3.1.1 Rising incidence of cancer and old age population 47
- 3.3.1.2 Increase in technological advancement in cancer diagnostics 48
- 3.3.1.3 Increase in healthcare expenditure 50
- 3.3.1.4 Infrastructure and investments by government and private companies 50
- 3.3.1.5 emerging markets and increasing awareness of various cancers 51
- 3.3.1.6 Personalized medicine 52
- 3.3.1.7 Mandatory early screening 53
- 3.3.2 RESTRAINTS AND THREATS 54
- 3.3.2.1 High cost of advanced technologies 54
- 3.3.2.2 Lack of skilled professionals hampering the growth of cancer diagnostics market 55
- 3.3.2.3 Product recall due to manufacturing and quality issues 56
- 3.3.2.4 Stringent regulations 57
- 3.3.2.5 Lack of reimbursement 58
- 3.3.1 DRIVERS AND OPPORTUNITY 47
- 3.4 MARKET SHARE ANALYSIS 59
- 3.4.1 CANCER DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS 59
- 3.5 REGULATORY AFFAIRS 64
- 3.5.1 U.S. 66
- 3.5.2 EUROPE 66
- 3.5.3 CHINA 68
- 3.5.4 INDIA 69
- 3.5.5 JAPAN 70
- 3.5.6 AUSTRALIA 70
- 3.5.7 SOUTH KOREA 71
- 3.6 REIMBURSEMENT SCENARIO 72
- 3.7 CLINICAL TRIALS 73
- 3.7.1 CTDNA CLINICALTRIALS 73
- 3.7.2 CFDNA CLINICALTRIALS 74
- 3.7.3 CIRCULATING TUMOR CELLS 75
- 3.7.4 COMPANION DIAGNOSTICS 76
- 3.7.5 IMMUNOASSAYS 78
- 3.8 PORTER’S FIVE FORCE ANALYSIS 78
- 3.8.1 THREAT OF NEW ENTRANTS 79
- 3.8.2 THREAT OF SUBSTITUTES 80
- 3.8.3 COMPETITIVE RIVALRY 80
- 3.8.4 BARGAINING POWER OF SUPPLIERS 81
- 3.8.5 BARGAINING POWER OF BUYERS 82
4 CANCER DIAGNOSTICS PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM) 83
- 4.1 RESEARCH METHODOLOGY 83
- 4.2 FORECAST METHODOLOGY 83
- 4.3 NORTH AMERICA CANCER DIAGNOSIS ADDRESSABLE MARKET 83
- 4.3.1 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM) 83
- 4.3.1.1 Early Screening: 83
- 4.3.1.2 U.S. colorectal cancer diagnosis, companion diagnostics, prognosis and
recurrence monitoring total addressable market (TAM) 84
- 4.3.2 U.S. BREAST CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM) 86
- 4.3.2.1 Early Screening 86
- 4.3.2.2 U.S. breast cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (TAM): 87
- 4.3.3 U.S. PROSTATE CANCER DIAGNOSTICS TOTAL ADDRESSABLE
- 4.3.1 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET PENETRATION AND TOTAL ADDRESSABLE MARKET (TAM) 83
MARKET (TAM) 88
- 4.3.3.1 Early Screening: 88
- 4.3.3.2 U.S. prostate cancer diagnosis, companion diagnostics, prognosis and
recurrence monitoring total addressable market (TAM) 89
- 4.3.4 U.S. LUNG CANCER DIAGNOSTICS TOTAL ADDRESSABLE MARKET (TAM) 91
- 4.3.4.1 Early Screening: 91
- 4.3.4.2 U.S. lung cancer diagnosis, companion diagnostics, prognosis and recurrence monitoring total addressable market (tam): 92
- 4.3.5 U.S. OTHER CANCER DIAGNOSIS, COMPANION DIAGNOSTICS,
PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE
MARKET (TAM) 93
- 4.3.6 REST OF N.A. CANCER DIAGNOSIS, COMPANION DIAGNOSTICS,
PROGNOSIS AND RECURRENCE MONITORING TOTAL
ADDRESSABLE MARKET (TAM) 94
- 4.4 EUROPE CANCER DIAGNOSIS ADDRESSABLE MARKET 95
- 4.4.1 EUROPE CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS
AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM) 95
- 4.5 APAC CANCER DIAGNOSIS ADDRESSABLE MARKET 97
- 4.5.1 APAC CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS
AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM) 97
- 4.6 ROW CANCER DIAGNOSIS ADDRESSABLE MARKET 98
- 4.6.1 ROW CANCER DIAGNOSIS, COMPANION DIAGNOSTICS, PROGNOSIS AND RECURRENCE MONITORING TOTAL ADDRESSABLE MARKET (TAM) 98
- 4.7 CANCER CARE GLOBAL ADDRESSABLE MARKET 99
- 4.7.1 EARLY SCREENING GLOBAL TOTAL ADDRESSABLE MARKET
BY CANCER TYPE AND BY REGION 99
- 4.7.2 PROGNOSIS MONITORING GLOBAL TOTAL ADDRESSABLE MARKET
BY REGION 101
- 4.7.3 COMPANION DIAGNOSTICS GLOBAL TOTAL ADDRESSABLE MARKET
BY REGION 102
- 4.7.4 RECURRENCE MONITORING GLOBAL TOTAL ADDRESSABLE MARKET
BY REGION 103
5 CANCER DIANOSTICS GLOBAL MARKET, BY TECHNOLOGY 104
- 5.1 INTRODUCTION 104
- 5.2 IMMUNOASSAYS 106
- 5.2.1 IMMUNOHISTOCHEMISTRY (IHC) 109
- 5.2.2 ENZYME LINKED IMMUNO SORBENT ASSAY (ELISA) 111
- 5.3.3 OTHER IMMUNOASSAYS 112
- 5.4 MOLECULAR BASED ASSAYS 118
- 5.4.1 IN-SITU HYBRIDIZATION 121
- 5.4.2 POLYMERASE CHAIN REACTION (PCR) 123
- 5.4.3 MICROARRAY 125
- 5.4.4 SEQUENCING 126
- 5.5 OTHERS 128
6 CANCER DIAGNOSTICS GLOBAL MARKET, BY SAMPLE SOURCE 130
- 6.1 INTRODUCTION 130
- 6.2 BLOOD 132
- 6.3 TISSUE 135
- 6.4 OTHERS 137
7 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET, BY CANCER TYPE 141
- 7.1 INTRODUCTION 141
- 7.2 CANCER TYPES 143
- 7.2.1 LUNG CANCER 144
- 7.2.2 BREAST CANCER 146
- 7.2.3 COLORECTAL CANCER 148
- 7.2.4 PROSTATE CANCER 149
- 7.2.5 LIVER CANCER 151
- 7.2.6 OVARIAN CANCER 152
- 7.2.7 OTHERS 154
8 CANCER DIAGNOSTICS APPLICATION GLOBAL MARKET,
BY CANCER CARE 158
- 8.1 INTRODUCTION 158
- 8.2 DIAGNOSIS 161
- 8.3 EARLY SCREENING 163
- 8.4 COMPANION DIAGNOSIS 165
- 8.5 PROGNOSIS 167
- 8.6 RECURRENCE MONITORING 169
9 CANCER DIAGNOSTICS GLOBAL MARKET, BY END-USERS 171
- 9.1 INTRODUCTION 171
- 9.2 HOSPITALS 174
- 9.3 CLINICAL/CENTRALIZED LABORATORIES 176
- 9.4 OTHERS 178
10 CANCER DIAGNOSTICS GLOBAL MARKET BY REGION 181
- 10.1 INTRODUCTION 181
- 10.2 NORTH AMERICA 185
- 10.2.1 U.S. 201
- 10.2.2 REST OF NORTH AMERICA 206
- 10.3 EUROPE 211
- 10.3.1 GERMANY 228
- 10.3.2 FRANCE 232
- 10.3.3 UNITED KINGDOM 236
- 10.3.4 REST OF EUROPE 240
- 10.4 ASIA-PACIFIC 245
- 10.4.1 JAPAN 261
- 10.4.2 CHINA 266
- 10.4.3 INDIA 270
- 10.4.4 REST OF ASIA-PACIFIC 275
- 10.5 REST OF THE WORLD 279
- 10.5.1 BRAZIL 296
- 10.5.2 REST OF LATIN AMERICA 300
- 10.5.3 MIDDLE EAST AND OTHER COUNTRIES 304
11 COMPETITIVE LANDSCAPE 309
- 11.1 INTRODUCTION 309
- 11.2 APPROVALS 310
- 11.3 COLLABORATION 316
- 11.4 NEW PRODUCT LAUNCHES 319
- 11.5 ACQUSTIONS 321
- 11.6 OTHERS 323
12 MAJOR COMPANIES 328
- 12.1 ABBOTT LABORATORIES 328
- 12.1.1 OVERVIEW 328
- 12.1.2 FINANCIALS 329
- 12.1.3 PRODUCT PORTFOLIO 332
- 12.1.4 KEY DEVELOPMENTS 332
- 12.1.5 BUSINESS STRATEGY 332
- 12.1.6 SWOT ANALYSIS 333
- 12.2 AGILENT TECHNOLOGIES, INC 334
- 12.2.1 OVERVIEW 334
- 12.2.2 FINANCIALS 335
- 12.2.3 PRODUCT PORTFOLIO 336
- 12.2.4 KEY DEVELOPMENTS 337
- 12.2.5 BUSINESS STRATEGY 339
- 12.2.6 SWOT ANALYSIS 340
- 12.3 DANAHER CORPORATION 341
- 12.3.1 OVERVIEW 341
- 12.3.2 FINANCIALS 342
- 12.3.3 PRODUCT PORTFOLIO 344
- 12.3.4 KEY DEVELOPMENTS 345
- 12.3.5 BUSINESS STRATEGY 345
- 12.3.6 SWOT ANALYSIS 346
- 12.4 EXACT SCIENCES CORPORATION 347
- 12.4.1 OVERVIEW 347
- 12.4.2 FINANCIALS 348
- 12.4.3 PRODUCT PORTFOLIO 350
- 12.4.4 KEY DEVELOPMENTS 350
- 12.4.5 BUSINESS STRATEGY 352
- 12.4.6 SWOT ANALYSIS 353
- 12.5 GUARDANT HEALTH, INC. 354
- 12.5.1 OVERVIEW 354
- 12.5.2 FINANCIALS 355
- 12.5.3 PRODUCT PORTFOLIO 357
- 12.5.4 KEY DEVELOPMENTS 357
- 12.5.5 BUSINESS STRATEGY 359
- 12.5.6 SWOT ANALYSIS 360
- 12.6 HOLOGIC, INC. 361
- 12.6.1 OVERVIEW 361
- 12.6.2 FINANCIALS 362
- 12.6.3 PRODUCT PORTFOLIO 365
- 12.6.4 KEY DEVELOPMENTS 365
- 12.6.5 BUSINESS STRATEGY 366
- 12.6.6 SWOT ANALYSIS 366
- 12.7 MYRIAD GENETICS, INC. 367
- 12.7.1 OVERVIEW 367
- 12.7.2 FINANCIALS 368
- 12.7.3 PRODUCT PORTFOLIO 371
- 12.7.4 KEY DEVELOPMENTS 371
- 12.7.5 BUSINESS STRATEGY 376
- 12.7.6 SWOT ANALYSIS 377
- 12.8 QIAGEN N.V. 378
- 12.8.1 OVERVIEW 378
- 12.8.2 FINANCIALS 379
- 12.8.3 PRODUCT PORTFOLIO 382
- 12.8.4 KEY DEVELOPMENTS 384
- 12.8.5 BUSINESS STRATEGY 386
- 12.8.6 SWOT ANALYSIS 388
- 12.9 ROCHE 389
- 12.9.1 OVERVIEW 389
- 12.9.2 FINANCIALS 390
- 12.9.3 PRODUCT PORTFOLIO 393
- 12.9.4 KEY DEVELOPMENTS 394
- 12.9.5 BUSINESS STRATEGY 397
- 12.9.6 SWOT ANALYSIS 398
- 12.10 SIEMENS HEALTHINEERS 399
- 12.10.1 OVERVIEW 399
- 12.10.2 FINANCIALS 400
- 12.10.3 PRODUCT PORTFOLIO 402
- 12.10.4 KEY DEVELOPMENTS 403
- 12.10.5 BUSINESS STRATEGY 403
Summary:
Get latest Market Research Reports on Cancer Diagnostics. Industry analysis & Market Report on Cancer Diagnostics is a syndicated market report, published as Cancer Diagnostics Global Market - Forecast to 2026. It is complete Research Study and Industry Analysis of Cancer Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
